Novartis AG said the Food and Drug Administration approved Amturnide, a high blood pressure combination pill that includes Novartis' drug Tekturna.
The Food and Drug Administration said that Abbott Laboratories is recalling up to 359 million testing strips used by diabetics because they can give falsely low blood sugar readings.
Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said they are asking the Food and Drug Administration to expand approval for their type 2 diabetes drug Byetta.
Two Fold Software Limited has created a web reporting module for its Qualoupe LIMS solution that allows organisations such as contract laboratories or manufacturing companies to access and run LIMS reports on demand in a more cost-efficient way.
SGE Analytical Science has been awarded a grant to help develop a new diamond-like coating technology. Diamond-like coating technology, or plasma-activated high-frequency vacuum deposition, has low friction and is extremely durable.
Merrion Pharmaceuticals Plc announced the signing of a Collaboration and Option agreement with Novo Nordisk. The agreement will evaluate the ability of Merrion's patented GIPET technology to boost the oral bioavailability of an undisclosed compound.
MorphoSys AG has received a clinical milestone payment from Centocor Ortho Biotech Inc. for a clinical trial application for a phase 1 clinical trial of a HuCAL-derived antibody in the therapeutic area of inflammatory and autoimmune diseases.
Researchers have found that leukemia patients whose cancers express higher levels of genes associated with cancer stem cells have a significantly poorer prognosis than patients with lower levels of the genes.
A study suggests that the presence of tumor cells in the circulating blood of patients with squamous cell cancer of the head and neck may predict disease recurrence and reduced survival; it also correlates with a worse outcome.
The American Heart Journal reported results of a clinical trial evaluating Amorcyte, Inc.’s lead product candidate, AMR-001 for the treatment of damaged heart muscle following acute myocardial infarction.
Tekmira Pharmaceuticals Corporation, a developer of RNA interference therapeutics, announced it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1.
Biogen Idec and Elan Corp. said they have applied to U.S. and European regulators to update prescribing information for the multiple sclerosis drug Tysabri to help classify the risk of a rare but serious brain infection.
Ligand Pharmaceuticals Inc. said it will receive a $1 million payment from Pfizer Inc. as part of a partnership for the potential contraceptive Tanaproget.
Two pharmaceutical companies have agreed to a settlement with two Nevada women who claimed hormone replacement drugs caused their breast cancer.
Teva Pharmaceutical Industries Ltd. said it will start selling a generic version of the diabetes drug Actos after settling a patent infringement lawsuit brought by the company that makes Actos, Takeda Pharmaceutical Co.